Antibody-drug conjugates (ADC), a fast-growing next-generation cancer treatment, have become an investment hotspot due to its potential to become mainstream globally, according to biopharmaceutical industry insiders.
To achieve sustainable growth and maximise revenue potential, companies should pursue differentiated product development and a global clinical strategy, according to Duality Biotherapeutics, which organised a biotech forum in Shanghai last week.
